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Abstract
Summary Anti-depressants are used largely, but have
serious side effects. We show that both selective serotonin
re-uptake inhibitors (SSRIs) and tricyclic anti-depressants
(TCAs) increase the risk of hip/femur fracture and that this
risk is time related and depends on the degree of serotonin
transporter inhibition. This should be considered when
prescribing anti-depressants to patients.
Introduction Anti-depressants are known to have serious side
effects. We examined the association between the use of anti-
depressants and the risk of hip/femur fractures with a special
focus on the relation with the degree of 5-hydroxytryptamine
transporter (5-HTT) inhibition and the duration of use.
Methods A case–control study was conducted within the
Dutch PHARMO-RLS database. Cases (n=6,763) were
adult patients with a first hip/femur fracture during the
study period. For each case, four controls (n=26341) were
matched by age, gender and geographic region.
Results The risk of hip/femur fracture increased with current
use of SSRIs (adjusted odds ratio (ORadj) 2.35 [95%
confidence interval (CI) 1.94–2.84]) and TCAs (ORadj 1.76
[95% CI 1.45–2.15]). The risk of hip/femur fracture declined
rapidly after discontinuation of use. The risk of hip/femur
fracture increased as the degree of 5-HTT inhibition of all
anti-depressants increased from ORadj 1.64 [95% CI 1.14–
2.35] for drugs with low 5-HTT inhibition to ORadj 2.31 [95%
CI 1.94–2.76] for those with high 5-HTT inhibiting properties.
Conclusion Current use of both SSRIs and TCAs increase
hip/femur fracture risk. Further studies are needed to elucidate
the mechanistic pathways and the relation with the underlying
pathophysiology. Until then, the elevated fracture risk should
be considered when prescribing anti-depressants.
Keywords Duration of use . Fracture . Risk . SSRI .
5-HTT inhibition
Introduction
Depression is one of the most important mental health
problems especially in the elderly and is associated with a
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poor natural history, reduced quality of life, increased
utilisation of medical health services and high mortality [1–
4]. Although depression can be treated effectively with
tricyclic anti-depressants (TCAs), many users experience
cardiovascular (e.g. orthostatic hypotension) and anti-
cholinergic side effects (e.g. visual disturbances), which
both may increase the risk of falling and thereby of
fractures. The newer generation of anti-depressants, includ-
ing the selective serotonin re-uptake inhibitors (SSRIs), are
considered as effective as the TCAs but with less
bothersome side effects. Its use has increased over the last
decade [5–7]. Some studies investigating the risk of falls
with anti-depressants have reported no significant difference
in risk for SSRIs and TCAs [8, 9].
Falls increase the risk of fracture, especially of the hip or
femur in the elderly [10], with significant consequences for
the individual and healthcare providers in terms of the
impact on long-term morbidity, mortality and healthcare
costs [11–14]. Several epidemiological studies have
reported an increased risk of fracture with anti-depressant
use [9, 15–17]. One explanation is that the increased
fracture risk is mediated simply by falling [8]. Another
explanation lies in the potential for anti-depressants to
affect the micro-architecture of bone. Functional serotonin
(5-hydroxytryptamine, 5-HT) receptors and transporter
systems have been localised on osteoblasts, osteoclasts
and osteocytes [18–22] and 5-HT stimulates proliferation of
osteoblast precursor cells in vitro [23]. Thus, drugs that
block 5-HT re-uptake could affect bone metabolism and
have a negative impact on bone micro-architecture. This
has been illustrated by a recent case–control study
conducted in Denmark, which reported an increased risk
of fractures with an increased degree of blocking of the
serotonin system [24].
The aim of this study was to examine the association
between the use of anti-depressants and the risk of hip/
femur fractures, with a special focus on the relation with the
degree of 5-hydroxytryptamine transporter (5-HTT) inhibi-




We conducted a case–control study within the Dutch
PHARMO Record Linkage System (RLS) (www.pharmo.nl).
The database includes the demographic details and com-
plete medication histories for about one million
community-dwelling residents in The Netherlands repre-
senting some 7% of the general population. Data are linked
to hospital discharge records as well as several other health
registries, including pathology, clinical laboratory findings
and general practitioner data [25]. Almost every individual
in The Netherlands is registered with a single community
pharmacy, independent of prescriber and irrespective of
their health insurance or socio-economic status. Pharmacy
records have a high degree of completeness with regards to
dispensed drugs [26, 27]. Pharmacy data include informa-
tion about the drug dispensed, the date of dispensing, the
prescriber, the amount dispensed, the prescribed dosage
regimen and the estimated duration of use. Hospital
discharge records include detailed information on date of
admission, discharge diagnoses and procedures. Validation
studies on PHARMO RLS have confirmed a high level of
data completeness and validity [28–30]. During data
collection, the privacy and confidentiality of patients is
maintained and complies with the Dutch Data Protection
Act.
Study population
Data were collected for the period 1 January 1991 to 31
December 2002. Cases were patients aged 18 years and
older with a record for a first fracture of the hip or femur
during the study period. The date of hospital admission was
used to define the index date. Each case was matched by
year of birth, sex and geographical region to up to four
control patients without any evidence of ever having
sustained a fracture. The index date for each control was
the same as the date of fracture for the matched case.
Exposure assessment
Exposure to anti-depressants was determined by reviewing
prescription information before the index date. Current
users were defined as individuals who had received a
prescription for a TCA, an SSRI or other anti-depressant
within a 30-day period before the index date. Recent users
were individuals whose most recent prescription was issued
31–90 days before the index date, and past users were those
whose most recent prescription had been issued more than
3 months (>90 days) before the index date. Patients with a
history of using more than one type of anti-depressant
before the index date were classified as appropriate, e.g. a
current user of an SSRI may also qualify as a current user
of a TCA. The average daily dose was calculated by
dividing the cumulative exposure by the total treatment
time. Dose equivalencies of anti-depressants were applied
from the WHO defined daily dose (DDD) [31] and were
expressed as paroxetine equivalents (SSRIs) or amitripty-
line equivalents (TCAs). The extent of 5-HTT inhibition
was determined for each anti-depressant with reference to
Goodman and Gilman’s ‘The Pharmacological Basis of
Therapeutics’ [32] (Table 1).
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For each prescription, the expected duration of use (in
days) was based on how the drug was supplied and the
prescribed daily dose. If there were missing data on the total
drug supply or written dosage instruction, the expected
duration of use (based on the median duration for a
prescription from patients of similar age and sex) was taken.
When repeat prescriptions were issued, the expected duration
of use period was extended according to the expected duration
of the repeat prescription. In the event of overlap between two
prescriptions (i.e. a repeat prescription given before the
expected end date of a previous prescription), the ‘overlap’
days were added to the theoretical end date of the repeat
prescription. If the gap between any consecutive prescriptions
was 6 months or less, exposure was deemed to be continuous.
Potential confounders
The records of cases and controls were assessed for potential
confounding variables, including use within the 3 months
before the index date of a benzodiazepine; use within the
6 months before the index date of an anti-psychotic (other
than lithium), lithium, an anti-Parkinson drug, anti-
convulsant, oral or inhaled glucocorticoid, bronchodilator,
hormone replacement therapy, a disease-modifying anti-
rheumatic drug (DMARD), anti-arrhythmic, thiazide diuretic,
beta-blocker, drug for diabetes, metoclopramide, morphine/
opiate or two or more prescriptions for an non-steroidal anti-
inflammatory drug (NSAID); and a history at any time of
hospitalisation for cardiovascular disease, malignant neo-
plasm, inflammatory bowel disease, rheumatoid disease,
obstructive airway disease, impaired renal function, mental
disorder or cerebrovascular disease. We have chosen a
different time window for benzodiazepines, because in The
Netherlands, benzodiazepines are dispensed for periods up to
1 month and other drugs for periods up to 3 months.
Statistical analysis
Conditional logistic regression analysis was used to
estimate the risk of hip/femur fracture associated with the
use of TCAs, SSRIs and the various confounding variables
(SAS version 9.1.3, PHREG procedure) and were
expressed as odds ratios (OR) with corresponding 95%
confidence intervals (CI). Adjusted odds ratios (ORadj) for
hip/femur fracture were estimated by comparing anti-
depressant use with no use using conditional logistic
regression analysis. Final regression models were deter-
mined by stepwise backward elimination using a signifi-
cance level of 0.05. We stratified the study population to
assess the risk with current use by age and sex.
Further analyses were conducted to evaluate the risk of
fracture associated with current exposure to anti-
depressants versus no use grouping current users according
to the daily dose of anti-depressant prescribed and accord-
ing to the degree of 5-HTT inhibition expected. Smoothing
spline regression plots (SAS version 9.1.3) were used to
visualise the longitudinal relationship between the risk of
fracture and (a) the time between the index date and last
dispensing of an anti-depressant (recency of use) and (b)
the duration of continuous use. The population attributable
risk (PAR) was estimated using the following formula:
PAR% ¼ Pe OR 1ð Þ
1þ Pe OR 1ð Þ  100:
The prevalence (Pe) of anti-depressant use was derived from
national prescribing figures in 2003, www.gipdatabank.nl.
Results
We identified 6,763 patients who suffered a hip/femur
fracture. These cases were matched to 26,341 controls. The
mean age of cases and controls was 75 years and 73% were
female (Table 2). The mean period of time with prescription
information before the index date was 4.1 years. Prescrip-
tions for paroxetine accounted for 50% of the prescriptions
issued for an SSRI (25,131/50,287). Most of the other SSRI
prescriptions were for fluoxetine (23.4%) or fluvoxamine
(20.3%). Amitriptyline (46.6%) and clomipramine (23.1%)
Degree of serotonin transporter inhibition (inhibition constant in nM)
Low (>10) Intermediate (>1≤10) High (≤1) Not classified
Desipramine Imipramine Clomipramine Opipramol
Nortriptyline Amitriptyline Fluoxetine Dosulepin






Table 1 Drugs grouped accord-
ing to the degree of serotonin
transporter inhibition [31]
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accounted for the majority of TCA prescriptions (n=
59,836).
Table 2 shows that compared with controls, cases were
significantly more likely to have used a benzodiazepine in
the previous 3 months and/or an anti-depressant, an anti-
psychotic, anti-convulsant, oral glucocorticoid, opiate or
drug for Parkinson’s disease within the previous 6 months.
In addition, cases were significantly more likely than
controls to have a history of cerebrovascular disease or
malignant neoplasm.
Table 3 provides crude and adjusted risk estimates for
hip/femur fracture associated with anti-depressant use
according to recency of use, and the results of analyses
amongst current users stratified by sex and age. Compared
with individuals who had never used the anti-depressant in
question, the risk of hip/femur fracture increased with
current use of SSRIs (crude OR 2.88 [95% CI 2.40–3.46])
and TCAs (crude OR 2.22 [95% CI 1.84–2.68]). After
adjustment for other variables associated with fracture risk,
the ORs remained significantly increased (ORadj 2.35 [95%
CI 1.94–2.84] for SSRIs and 1.76 [95% CI 1.45–2.15] for
TCAs). Under the assumption that the risk of hip fracture
amongst users of SSRIs/TCAs is similar in the period
1991–2002 and 2003, we estimated that the population
attributable risk of hip fracture is 1.1% for current users of
TCAs and 4.4% for current users of SSRIs. For SSRIs,
there was some effect modification by sex (ORadj 2.50
[95% CI 2.03–3.08] for females and 1.72 [95% CI 1.08–
2.74] for males) and age (ORadj 2.00 [95% CI 1.21–3.29]
for SSRI users aged 18–69 years and 2.39 [95% CI 1.94–
2.94] for SSRI users aged ≥70 years).
Figure 1a shows a clear association between the time
since the last dispensing of an SSRI and the risk of hip/
femur fracture. The risk of hip/femur fracture, which was
increased in current users, declined rapidly after discontin-
uation of use. A similar trend was observed for users of
TCAs (Fig. 1b). The risk of hip/femur fracture was
increased during the first few months of continuous use of
SSRIs, peaking at about 8 months, and remained elevated
after about 1.5 years of continuous use (Fig. 2a). Short-term
exposure to TCAs showed a rapid increase in hip/femur
fracture risk that declined after 1 year of exposure (Fig. 2b).
Table 4 presents the results of analysis amongst current
users according to the average daily dose of anti-depressant
used. Compared with individuals who had never used an
SSRI, medium and high dose SSRI users had a greater risk
of fracture than low dose users, although the differences
were not statistically significant. There was no evidence to
suggest a dose–response relationship for the risk of hip/
femur fracture with TCA use.
Table 5 presents the results of analyses amongst all anti-
depressant users, where current users were grouped
according to the degree of 5-HTT inhibition afforded by
the different drugs. The risk of hip/femur fracture increased
as the degree of 5-HTT inhibition increased from ORadj
1.64 [95% CI 1.14–2.35] for drugs with low 5-HTT
Cases (n=6,763) Controls (n=26,341) Crude odds ratio (95% CI)
Age
18 to 49 years 452 (6.7%) 1,808 (6.9%)
50 to 69 years 1,061 (15.7%) 4,239 (16.1%)
≥70 years 5,250 (77.6%) 20,294 (77.0%)
Mean age in years 75.7 75.3
Number of females 4,929 (72.9%) 19,138 (72.7%)
Drug use before the index date
TCAs 256 (3.8%) 591 (2.2%) 1.75 (1.51–2.04)
SSRIs 315 (4.7%) 582 (2.2%) 2.20 (1.91–2.54)
Anti-psychoticsa 412 (6.1%) 921 (3.5%) 1.79 (1.58–2.02)
Anti-convulsantsa 242 (3.6%) 431 (1.6%) 2.23 (1.90–2.61)
Benzodiazepinesb 967 (14.3%) 2,751 (10.4%) 1.44 (1.33–1.56)
Oral glucocorticosteroidsa 366 (5.4%) 918 (3.5%) 1.59 (1.40–1.80)
Thiazide diureticsa 146 (2.2%) 557 (2.1%) 1.01 (0.84–1.21)
Opiatesa 253 (3.7%) 455 (1.7%) 2.24 (1.92–2.63)
Anti-Parkinson drugsa 397 (5.9%) 833 (3.2%) 1.94 (1.71–2.19)
≥2 NSAID prescriptionsa 929 (13.7%) 2,584 (9.8%) 1.46 (1.35–1.59)
Hospitalisation before the index date
Cardiovascular disease 359 (5.3%) 1,289 (4.9%) 1.10 (0.98–1.25)
Cerebrovascular disease 296 (4.4%) 565 (2.1%) 2.12 (1.84–2.45)
Malignant neoplasms 341 (5.0%) 1,021 (3.9%) 1.54 (1.37–1.74)
Table 2 Baseline characteristics





aWithin the 6 months before the
index date
bWithin the 3 months before the
index date
1708 Osteoporos Int (2009) 20:1705–1713
inhibition to ORadj 2.31 [95% CI 1.94–2.76] for those with
high 5-HTT inhibiting properties. Users of anti-depressants
with stronger anti-cholinergic properties, or a strong
potential to induce orthostatic hypotension, did not have
higher risks of hip fracture compared to users of anti-
depressants with weaker properties (data not shown).
Discussion
This study has demonstrated an increased risk hip/femur
fracture for current users of SSRIs and TCAs. For both
SSRIs and TCAs, the increased risk declined rapidly about
6 months after discontinuation of use. Fracture risk
associated with SSRIs and TCAs was the greatest during
the first few months of use and an elevated risk persisted
with continuous use of SSRIs. We found some evidence for
a dose effect with SSRIs but not TCAs. Furthermore, we
found evidence to suggest that the risk of fracture was
greater amongst people using anti-depressants with a higher
degree of 5-HTT inhibition.
The magnitude of increased fracture risk with anti-
depressant use described here is in line with findings from
other epidemiological studies [9, 15–17, 24]. Those studies
that compared risk with SSRIs and TCAs [9, 15, 16]
similarly reported no difference in risk. There is also
evidence to support our observation of an increased risk
during the initial period of exposure [15, 16]. Richards et
al. [17] investigated fracture risk with SSRIs and reported a
dose effect and a sustained elevation in risk with prolonged
use. Vestergaard et al. reported a dose-dependent increase in
fracture risk for sedating TCAs and most SSRIs. Further-
more, they also found an association between the increase
in risk of any fracture and the inhibition of the serotonin
transporter system [24].
We observed a similar increase in fracture risk for users
of SSRIs and TCAs. The explanation for that increased
fracture risk may be related simply to an increase in the risk
of falls associated with anti-depressant use, especially as
there is evidence to suggest that both SSRIs and TCAs are
associated with an increased risk of fall. A large study of
nursing home residents showed that, compared with non-
users and after adjusting for potential confounders, the risk
of falls was similar in new users of TCAs and SSRIs. The
association was dose dependent and the increased risk
persisted through the first 180 days of use and beyond [8].
TCAs are known to inhibit cardiovascular Na+, Ca2+ and
K+ channels which can lead to life-threatening arrhythmias.
SSRI use has been associated with an increased risk of
syncope [33], postural hypotension and dizziness [34]











Never exposed 6,174 25,041 1.00 – Referent
Past use (>90 days before the index date) 303 820 1.52 1.33–1.75 1.23 1.07–1.42
Recent use (31–90 days before the index date) 86 193 1.87 1.45–2.42 1.48 1.14–1.93
Current use (1–30 days before the index date) 200 287 2.88 2.40–3.46 2.35 1.94–2.84
Males 33 59 2.30 1.48–3.59 1.72 1.08–2.74
Females 167 228 3.02 2.46–3.70 2.50 2.03–3.08
Age 18–69 years 33 44 3.07 1.95–4.82 2.00 1.21–3.29
Age ≥70 years 167 243 2.84 2.32–3.48 2.39 1.94–2.94
Exposure to TCAs
Never exposed 6,175 24,864 1.00 – Referent
Past use (>90 days before the index date) 360 978 1.52 1.34–1.72 1.14 1.00–1.30
Recent use (31–90 days before the index date) 56 176 1.32 0.97–1.79 0.98 0.72–1.34
Current use (1–30 days before the index date) 172 323 2.22 1.84–2.68 1.76 1.45–2.15
Males 29 43 2.85 1.76–4.62 2.19 1.31–3.67
Females 143 280 2.11 1.72–2.60 1.69 1.36–2.09
Age 18–69 years 31 60 2.18 1.40–3.40 1.31 0.80–2.14
Age ≥70 years 141 263 2.22 1.80–2.74 1.81 1.46–2.25
a SSRI use was adjusted for (a) current use of an anti-depressant other than SSRI, (b) use in the past 3 months of a benzodiazepine; (c) use in the
past 6 months of oral corticosteroids, hormone replacement therapy, anti-psychotics, beta-blockers, opioids, anti-convulsants, drugs for diabetes,
more than two dispensings of an NSAID, DMARDs and metoclopramide and (d) a history of malignant neoplasms, mental disorders,
cerebrovascular diseases, obstructive airway diseases or inflammatory bowel diseases. TCA use was adjusted for current use of an anti-depressant
other than TCA and other potential confounders as listed above (b)–(d) for SSRI use
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during the early days of exposure, and both SSRIs and
TCAs can affect sleep patterns [35, 36], thereby increasing
the risk of falls [37].
Another explanation for the increased fracture risk
observed here is the effect of anti-depressants on bone
physiology. Functional 5-HT receptors are present in bone
cells and 5-HT stimulates proliferation of osteoblast
precursor cells in vitro [23]. There is emerging evidence
from animal studies that 5-HT is involved in bone
remodelling and can alter bone mineral density (BMD)
[18–20, 22]. Indeed, recent findings have shown that SSRIs
decrease BMD in animal models [38] and humans [17, 39–
41]. Such studies that compared BMD changes with
different anti-depressants reported no association between
TCA use and BMD [39, 40]. In a recent study of
osteoporotic fractures, it was observed that the use of
SSRIs (but not TCAs) in older women was independently
associated with an increased rate of hip bone loss (0.82%
reduction per year) [41], although there was limited
information on dose and duration of use.
To explore the possibility that fracture risk may be
directly related to inhibition of the 5-HTT system, we
grouped together the anti-depressants used according to the
degree of 5-HTT inhibition afforded. It was apparent that the
risk of hip/femur fracture increased as the degree of 5-HTT
inhibition increased. Whilst none of the risk estimates was
significantly different, a clear trend was evident and this
supports the possibility that stronger inhibition of the 5-HTT
system on the bone could cause a greater disruption of the
balance between osteoblasts and osteoclasts and hence have
a greater detrimental effect on bone micro-architecture.
Drug-induced changes in bone micro-architecture can be
rapid. Analysis of the micro-architecture of femur bone in
rats treated with 5-HT showed changes in trabecular bone
volume and an increased femoral stiffness after just
3 months [10]. Other drug exposures had demonstrated
similarly rapid effects on human bone, e.g. corticosteroids
[42, 43]. It is possible that a rapid change in bone micro-
architecture affected by anti-depressant use accounted for,
Fig. 1 a, b Recency of SSRI (a) and TCA (b) use before the index
date and risk of hip/femur fracture. Dashed lines and open dots: crude
ORs with 95% CI; solid lines and solid dots: adjusted ORs with 95%
CI. Adjustments were made for the same confounders as in Table 3
Fig. 2 a, b Recency of SSRI (a) and TCA (b) duration of continuous
use amongst current users before the index date and risk of hip/femur
fracture. Dashed lines and open dots: crude ORs with 95% CI; solid
lines and solid dots: adjusted ORs with 95% CI. Adjustments were
made for the same confounders as in Table 3
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or at least contributed to, the increased fracture risk during
the early months of exposure.
We found that as the duration of treatment with TCAs
increased, the risk of fracture declined, whereas the risk for
fracture with continuation of SSRIs fell after the initial
increase but remained somewhat elevated thereafter. It may
be that with chronic administration of anti-depressants,
adaptive changes occur [44]. These may result in an
adjustment to the cardiovascular effect of TCAs and SSRIs,
explaining the decrease in fracture risk after a few months
of use, whereas changes in bone physiology are not subject
to adaptive changes, explaining the sustained fracture risk
in SSRI users.
Limitations of our study include absence of potentially
confounding data on body mass index (BMI), smoking
status and exercise. In a US/Puerto Rican cohort study, it
was likely that lack of adjustment for BMI, current smoking
status, activities of daily living score, cognitive impairment
and Rosow–Breslau physical impairment scale accounted
for up to 30% of the increased risk of hip fractures amongst
users of SSRIs [45]. We do not anticipate that missing data
on these variables would have an important impact on our
findings; therefore, as if our ORs were decreased by 30%, a
positive association would remain. Another limitation lies
in the potential for confounding by indication, as depres-
sion itself is associated with an increased risk of falls and
fractures [46]. There is also the possibility of a channelling
effect whereby, for some frail patients with depression, an
SSRI was prescribed instead of a TCA because of the more
favourable side-effect profile anticipated. This could have
overestimated the risk associated with SSRIs observed here.
These unmeasured types of confounding as well as selection
bias (e.g. healthy user bias), which can change over time,
may be alternative explanations for our observed associa-
tions between fracture risk and duration of anti-depressant
use or discontinuation of anti-depressants. In Figs. 1 and 2,
data beyond 4 years are sparse, which makes extrapolation
uncertain. Lastly, the PAR calculation showed that 4.4% of
hip fractures in The Netherlands might be attributed to
current use of SSRI; however, given the previous limi-
tations and the susceptibility of our study for unmeasured
distortions, this figure should be interpreted with great care.
Table 5 Risk of hip/femur fracture by degree of serotonin (5-HT) transporter inhibition
Cases (n=6,763) Controls (n=26,341) Adjusted ORa 95% CI
Never exposed 5,677 23,698 Referent –
Past use (>90 days before the index date) 506 1,514 1.19 1.76–2.29
Recent use (31–90 days before the index date) 158 404 1.32 1.09–1.61
Current use (1–30 days before the index date) 422 725 2.01 1.76–1.29
Low 5-HT transporter inhibition 46 102 1.64 1.14–2.35
Medium 5-HT transporter inhibition 132 241 1.92 1.53–2.40
High 5-HT transporter inhibition 234 358 2.31 1.94–2.76
Not classified 10 24 1.44 0.67–3.04
a Adjustments were made for the confounders listed in the footnote of Table 3
Table 4 Current use of SSRIs and TCAs and the risk of hip/femur fracture by average daily dose
Average daily dose (DDD) Cases Controls Crude OR 95% CI Adjusted ORc 95% CI
Current SSRI usea
One prescription before the index date 16 30 2.15 1.17–3.96 1.72 0.92–3.21
Low (<0.5) 22 47 1.88 1.13–3.13 1.50 0.89–2.53
Medium (0.5–1.0) 77 95 3.40 2.51–4.62 2.77 2.03–3.80
High (>1.0) 85 115 3.08 2.31–4.09 2.49 1.86–3.34
Current TCA useb
One prescription before the index date 12 21 2.39 1.17–4.86 1.95 0.94–4.06
Low (<0.5) 95 186 2.13 1.66–2.74 1.73 1.33–2.24
Medium (0.5–1.0) 53 91 2.41 1.71–3.38 1.82 1.28–2.58
High (>1.0) 12 25 1.99 1.00–3.97 1.35 0.66–2.79
a Referent: never exposed to SSRIs
b Referent: never exposed to TCAs
c Adjustments were made for the confounders listed in the footnote of Table 3
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One of the strengths of this study is size of the population
available and the reliability of information on prescribing
and hospitalisations. Furthermore, the longitudinal nature of
recording has two advantages. First, to our knowledge, this
is the only study where duration of use analysis has allowed
speculation on the effects of anti-depressants on bone.
Second, this is the second study to evaluate the effect of 5-
HTT inhibition on fracture risk estimates.
In summary, our findings demonstrate that both SSRIs
and TCAs increase the risk of hip/femur fracture in current
users and that the risk increases with the degree of 5-HTT
inhibition afforded by different anti-depressants. We did not
find convincing evidence for a dose effect. The pathophys-
iology can be fall-related and/or bone-related. Further studies,
including controlled prospective trials, are needed to evaluate
the relative contribution of disease-related and treatment-
related effects to the increased risk of falls and hip/femur
fractures and to elucidate the pathophysiology. Until then,
physicians prescribing anti-depressants should consider the
elevated risk for fractures in elderly, possibly frail, people
using anti-depressants and value the rule: “start low, go slow”.
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